100.00% -0.735

Avenue Therapeutics Inc (ATXI)

Panoramica Notizia Cronologia dei prezzi Financials Perché ATXI Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Avenue Therapeutics Inc Stock (ATXI) Company Profile

Avenue Therapeutics Inc

Healthcare (1135)

Biotechnology (634)

Prossima data di guadagno

Ultimi documenti SEC

ATXI's Discussions on Twitter

Confronta ATXI con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ATXI Avenue Therapeutics Inc	0.00	0	0	-10.38M	-12.45M	-3.81
ARGX Argen X Se Adr	918.53	57.24B	3.06B	1.28B	447.35M	19.67
VRTX Vertex Pharmaceuticals Inc	435.52	110.12B	11.74B	3.68B	3.34B	14.19
INSM Insmed Inc	201.62	42.10B	447.02M	-1.18B	-906.14M	-6.1812
ONC Beone Medicines Ltd Adr	363.92	41.68B	4.98B	69.59M	525.67M	0.5197
REGN Regeneron Pharmaceuticals Inc	725.34	74.02B	14.25B	4.58B	3.88B	41.77

Avenue Therapeutics Inc Borsa (ATXI) Ultime notizie

Avenue Therapeutics Inc Azioni (ATXI) Dati Finanziari

Avenue Therapeutics Inc (ATXI)

Avenue Therapeutics Inc Stock (ATXI) Company Profile

Confronta ATXI con altri titoli

Avenue Therapeutics Inc Borsa (ATXI) Ultime notizie

Avenue Therapeutics Announces 2025 Annual Meeting Date - TipRanks

Village Farms International Leads with 282% Return in Recent Performance Surge - Markets Mojo

Village Farms International Leads with 275% Return in Recent Performance Surge - Markets Mojo

Avenue Therapeutics Leads Six-Month Stock Performance with 333.85% Return - Markets Mojo

Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times

Avenue Therapeutics Reports Improved Financials Amid Challenges - TipRanks

Village Farms International Leads Six-Month Stock Performance with 424.66% Return - Markets Mojo

Avenue Therapeutics Sells Baergic Bio to Axsome - TipRanks

ATXI SEC FilingsAvenue Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM) - The Globe and Mail

Village Farms International Leads with 418.66% Return in Recent Performance - Markets Mojo

Village Farms International Leads with 354.34% Return in Recent Performance - Markets Mojo

Axsome Therapeutics acquires Baergic Bio from Avenue Therapeutics - MSN

Axsome Therapeutics Eyes Baergic Bio: Is This the Next Big CNS Breakthrough? - Smartkarma

Axsome Therapeutics Buys Global Rights To AZD7325 To Expand Epilepsy Pipeline - Pulse 2.0

Deutsche Bank Sticks to Its Sell Rating for AstraZeneca (AZN) - The Globe and Mail

Nebius Group NV Leads Six-Month Stock Performance with 359.83% Return - Markets Mojo

Axsome acquires global rights to AstraZeneca’s epilepsy drug candidate By Investing.com - Investing.com Australia

Avenue shares rights to epilepsy drug candidate with Axsome in deal - Investing.com Nigeria

Axsome acquires global rights to AstraZeneca’s epilepsy drug candidate - Investing.com India

Axsome Therapeutics stock hits all-time high at 139.22 USD By Investing.com - Investing.com South Africa

Axsome Therapeutics stock hits all-time high at 139.22 USD - Investing.com India

Avenue Therapeutics (ATXI) Sells Baergic Bio to Axsome Therapeutics - GuruFocus

AZN Secures Deal with Axsome for Epilepsy Drug Development - GuruFocus

Avenue shares rights to epilepsy drug candidate with Axsome in deal By Investing.com - Investing.com South Africa

Axsome Therapeutics IncObtains Exclusive G - 富途牛牛

Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy - The Manila Times

OTC Markets Group Welcomes SUN SILVER LTD. to OTCQX - The Manila Times

Axsome adds AstraZeneca epilepsy candidate to pipeline through Avenue subsidiary acquisition - Fierce Biotech

Axsome Therapeutics, Inc. entered into an agreement to acquire Baergic Bio, Inc. from Avenue Therapeutics, Inc. for $79.3 million. - MarketScreener

Global Pain Management Devices Market Set to Expand Rapidly at a CAGR of ~8% by 2032 Amid Growing Preference for Minimally Invasive Solutions | DelveInsight - Business Upturn

Nebius Group NV Leads Six-Month Stock Performance with 374.29% Return - Markets Mojo

OVID PRE 14A: approvals for Series B conversion and warrants - Stock Titan

Can Dianthus Therapeutics Inc. stock attract ESG capital inflowsPortfolio Value Summary & AI Driven Price Forecasts - fcp.pa.gov.br

Lirum Therapeutics Announces FDA 'Study May Proceed” Letter Enabling Inclusion of LX-101 in the RAPID Platform Clinical Trial for Ewing Sarcoma and Desmoplastic Small Round Cell Tumor - The Manila Times

Lirum Therapeutics Announces FDA “Study May Proceed” Letter - GlobeNewswire

Head to Head Survey: Avenue Therapeutics (NASDAQ:ATXI) vs. Neoleukin Therapeutics (NASDAQ:NLTX) - Defense World

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million - The Manila Times

Denali Therapeutics (NASDAQ:DNLI) versus PureTech Health (NASDAQ:PRTC) Critical Comparison - Defense World

Xtrackers MSCI Kokusai Equity ETF (NYSEARCA:KOKU) Trading 1.4% Higher – Still a Buy? - Defense World

Nexus Industrial REIT (OTCMKTS:EFRTF) Shares Down 2.5% – Should You Sell? - Defense World

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million - The Manila Times

Apogee Therapeutics, Inc. Announces Closing of Public - GlobeNewswire

Avenue Therapeutics, Inc. (ATXI) stock price, news, quote and history - Yahoo

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering - GlobeNewswire

United States Drug Resistant Epilepsy Market 2025 | Industry Developments, Future Growth, Share & Industry Insights - openPR.com

Speedy Hire (LON:SDY) Shares Up 18.8% Following Insider Buying Activity - Defense World

Operating cash flow per share of Avenue Therapeutics, Inc. – LSX:A40BWJ - TradingView

Vital Farms, Inc. (VITL) Attracts New Investment from Park Avenue Securities - Yahoo Finance

Ceapro (OTCMKTS:CRPOF) and Avenue Therapeutics (NASDAQ:ATXI) Financial Contrast - Defense World

Affiliate of Pacific Avenue Capital Partners Completes the Acquisition of Pick Your Part from LKQ Corporation - Shreveport Times

Avenue Therapeutics Inc Azioni (ATXI) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a ATXI